diflucortolone and diflucortolone-valerate

Cutaneous Polyarteritis Nodosa (cPAN) was first described in 1931. cPAN is considered a rare disease, its true incidence is unknown. The age of onset is diverse. Most studies have shown no significant gender predominance. cPAN presents with distinct skin findings, such as a maculopapular rash, subcutaneous nodules, livedoid vasculitis, panniculitis, ischemic finger lesions, or erythematous patchy rash. Etiology is unclear. It is still believed to be an immune complex-mediated disease, although a possible mechanism recently proposed relates a familial form of the disease to impaired activity of Adenosine Deaminase 2. cPAN may reflect an underlying disease, infection or medical treatment. There is no consensus as to initial treatment, dosage and length of treatment. Patients with constitutional symptoms, visceral involvement, a more severe course of the disease, or high acute phase reactants, were treated mainly with systemic corticosteroids and/or cytotoxic agents for varying durations. However, persistence of cutaneous lesions has been documented. We describe a 14 year old male suffering from persistent cPAN, with no constitutional symptoms or involvement of internal organs. The patient was treated with a local corticosteroid-based ointment during exacerbations, until complete remission. Although reported in only one study, treatment with topical corticosteroid compound may result in significant improvement or complete regression of skin lesions in cPAN patients.

Topics: Administration, Topical; Adolescent; Anti-Inflammatory Agents; Biopsy; Diflucortolone; Humans; Male; Polyarteritis Nodosa; Skin; Skin Diseases; Treatment Outcome

Although influenza vaccine is thought to be effective and safe, it occasionally causes systemic reactions such as toxic epidermal necrolysis, bullous pemphigoid, lichen planus (LP), etc. The period of increased risk of developing these events was different depending on the immune responses induced by the vaccination. We report 3 cases of LP which appeared after an influenza vaccination. Our cases indicate that the period of increased risk of developing vaccine-related LP was concentrated within 2 weeks after vaccination, and that the vaccine alone represents a triggering factor necessary for immune alteration sufficient for the development of LP. Because these adverse events tend to develop over a predictable time course, the time of onset may give an important clue to the diagnosis of vaccine-related diseases. We suggest that a history of recent vaccination should be sought in all patients presenting with linear LP.

Topics: Aged; Anti-Inflammatory Agents; Buttocks; Clobetasol; Dexamethasone; Diflucortolone; Female; Humans; Influenza Vaccines; Leg; Lichen Planus; Middle Aged

Dermatomycoses are contagious superficial fungal infections, which are highly prevalent in developed and developing countries. Caused by a range of Epidermophyton, Microsporum and Trichophyton species, dermatomycoses manifest on glabrous skin as 'ringworm', an annular scaly lesion with a variable inflammatory component. Itch is the chief subjective symptom, particularly in tinea cruris. Unless lesions are extensive or resistant to local therapy, dermatomycoses of glabrous skin are treated with topical antifungal agents, such as imidazoles and allylamines. Studies show, however, that the addition of a topical corticosteroid to imidazole therapy increases the bioavailability and prolongs the activity of the antimycotic, while rapidly reducing inflammatory symptoms. Travocort is a combination of 1% isoconazole nitrate (ISN), a broad-spectrum imidazole with established antimicrobial activity and antimycotic efficacy, and 0.1% diflucortolone valerate (DFV), a potent topical corticosteroid with low systemic absorption and therefore a low risk of systemic glucocorticoid side-effects. In randomised, double-blind controlled clinical trials, Travocort therapy showed a more rapid onset of action, faster relief of itch and other inflammatory symptoms, improved overall therapeutic benefits and better mycological cure rate during the first 2 weeks of treatment compared with ISN monotherapy. Travocort is well tolerated and, because of prolonged ISN retention in the skin, provides antifungal protection against reinfection for some weeks after therapy.

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Child; Child, Preschool; Dermatomycoses; Diflucortolone; Double-Blind Method; Drug Combinations; Humans; Inflammation; Miconazole; Randomized Controlled Trials as Topic; Tinea; Treatment Outcome

Paederus dermatitis, a type of irritant contact dermatitis attributed to a Staphylinid beetle, is prevalent in most parts of the world. We studied 50 cases of Paederus dermatitis at the United Nations Hospital at Koidu Sierra Leone (West Africa), over a period of 6 months from Oct 2003 to Mar 2004. The objectives of the study were to determine clinical patterns of dermatitis and its response to topical steroids, with and without antibiotics. Patients with a definite history of contact with the insect were included in the study. Amongst these, 14 of the more severe cases were treated with oral prednisolone or intralesional triamcinolone acetonide. The remainder of the 36 patients were divided in two equal groups A and B. Patients in Group A were treated with topical diflucortolone valerate 0.001 percent and oral cetirizine hydrochloride; patients in group B were given oral ciprofloxacin in addition. In 50 patients studied, 43 (86%) were males and 7 (14%) were females. The neck was the most common site involved followed by face. Healing time ranged from 14 to 28 days and lesions in all the patients healed with residual dyschromia. Healing time was shorter in Group B patients in comparison with those in Group A. Paederus dermatitis in Sierra Leone is a relatively severe form of this dermatitis. The better response to a combination of topical steroids and oral antibiotics may indicate concurrent bacterial infection.

Topics: Administration, Oral; Administration, Topical; Adult; Animals; Anti-Bacterial Agents; Cetirizine; Ciprofloxacin; Coleoptera; Dermatitis, Irritant; Diflucortolone; Female; Glucocorticoids; Humans; Injections, Intralesional; Male; Prednisolone; Sierra Leone; Skin Diseases, Bacterial; Triamcinolone Acetonide

A double-blind, randomized clinical study was conducted to compare the efficacy and tolerability of twice-daily topical calcipotriol treatment with a combination treatment of calcipotriol once a day in the morning and diflucortolone valerate in the evening. Sixty-three patients with a clinical diagnosis of chronic plaque psoriasis and comparable psoriatic lesions on both sides of the body were included. After a washout phase of 1 week, psoriatic lesions were treated for 4 weeks with calcipotriol ointment twice daily on one side of the body and a combination of calcipotriol and diflucortolone valerate ointment on the other side. The treatment period was followed by a period of 4 weeks without any treatment. The psoriasis area and severity index (PASI) was used to compare the 2 groups. Furthermore, the overall therapeutic results were assessed independently by the investigators and by the patients. Both treatment regimens showed a significant, nearly identical, reduction in PASI. The mean PASI for calcipotriol alone was 5.7 at baseline, 1.9 after 4 weeks of treatment and 3.8 at the end of the follow-up period. For combination therapy, these values were 5.7, 1.8 and 3.8, respectively. There was a statistically significant advantage in favor of combined calcipotriol and diflucortolone valerate treatment at weeks 1 and 2 (p < 0.05); however, at the end of the treatment phase the difference between the 2 therapies was not significant. Subjective evaluation of efficacy by both the investigators and the patients revealed no difference between the 2 treatments. The frequency of side effects (e.g. irritation) was low in both groups. In conclusion, both therapies were effective for the treatment of chronic plaque-type psoriatic lesions. The combination of calcipotriol and a topical steroid appeared to produce a more rapid clinical response and was shown to be as effective as calcipotriol therapy alone.

Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Calcitriol; Dermatologic Agents; Diflucortolone; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome

Psychosocial factors have been implicated in the onset and exacerbation of psoriasis.. We conducted a randomized, placebo-controlled, double-blind study to investigate the effect of an antidepressant agent, moclobemide, on the course of psoriasis vulgaris.. Sixty subjects were enrolled in the study. Patients were randomly assigned to treatment groups. Patients received moclobemide 450 mg/day or placebo and a topical corticosteroid ointment (diflucortolone valerate) for 6 weeks. Patients were examined at the beginning of the study and at 2-week intervals. At each visit, the severity of psoriasis and psychologic status were evaluated with the Psoriasis Area Severity Index (PASI), Beck Depression Inventory (BDI), Hamilton Rating Scale for Anxiety (HAM-A), Hamilton Rating Scale for Depression (HRS-D-17) and State-Trait Anxiety Inventory including state (STAI-1) and trait anxiety (STAI-2).. Treatment efficacy was able to be evaluated in 22 patients in the moclobemide-treated group and in 20 in the placebo-treated group. The improvement rates in PASI, BDI, STAI-1, and HAM-A scores were significantly higher in the moclobemide treatment group. The level of state anxiety was diminished in the moclobemide group. Correlation was positive between improvement rates of the psoriatic lesions and state anxiety in all patients.. Our results suggest that an antidepressant drug is useful in the treatment of psoriasis.

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antidepressive Agents; Benzamides; Diflucortolone; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Moclobemide; Psoriasis; Psychological Tests

The percutaneous absorption of diflucortolone-21-valerate (DFV) and its effect on the pituitary adrenal system were investigated during large skin area treatment (20 g ointment twice a day for 8 days) of two groups of healthy volunteers with Nerisona and Nerisalic ointment, respectively. Plasma levels of diflucortolone, cortisol and dehydroepiandrosterone (DHEA) were measured in both groups whereas plasma levels of salicylic acid were measured additionally in volunteers treated with Nerisalic. No differences, neither in percutaneous absorption of DFV nor in effects on cortisol and DHEA were found between the two treatment groups. There was a slight reduction in cortisol levels under both treatments, but the circadian rhythm was not disturbed. Mean salicylic acid plasma levels under high-dose topical Nerisalic treatment were about 50-fold below levels where toxicity may be expected.

Topics: Adult; Dehydroepiandrosterone; Diflucortolone; Female; Humans; Hydrocortisone; Male; Salicylates; Salicylic Acid; Skin Absorption

In a double-blind, parallel-group, multicenter, comparative trial in 120 evaluable patients with chronic, localized atopic dermatitis or lichen simplex chronicus, the success rate (described as "healed" and "marked improvement") was 91.5% in patients treated with halobetasol propionate ointment and 83.6% in those in the diflucortolone valerate treatment group. Of patients treated with halobetasol propionate ointment, 40.7% reported healing within 17 days, whereas of those in the diflucortolone valerate treatment group, 32.8% reported healing within that time. Early onset of therapeutic effect, that is, within 3 days of the start of treatment, was reported in a higher percentage of patients treated with halobetasol propionate ointment than in those treated with diflucortolone valerate ointment (70% versus 59%). Adverse effects at the site of application were less frequently reported in patients belonging to the halobetasol propionate treatment group than in those treated with diflucortolone valerate ointment (3% versus 8%).

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Austria; Chronic Disease; Clobetasol; Dermatitis, Atopic; Diflucortolone; Double-Blind Method; Female; Humans; Male; Middle Aged; Neurodermatitis; Ointments; Patient Satisfaction; Remission Induction; Vasoconstrictor Agents; Wound Healing

Topics: Chronic Disease; Diflucortolone; Fluocortolone; Humans; Lichen Planus; Occlusive Dressings; Ointments; Random Allocation

We report on 161 patients suffering from inflammatory dermatoses on hands, forearms, and lower legs who had been initially treated with 0.1% difluocortolone valerate. During the maintenance therapy carried out over a period of 3 to 4 weeks, we tested the efficacy of Kamillosan cream vs. 0.25% hydrocortisone, 0.75% fluocortin butyl ester, and 5% bufexamac in a bilateral comparative study. For the indications tested Kamillosan cream showed more or less equieffective therapeutic results as compared to 0.25% hydrocortisone. It is superior, however, to the non-steroidal anti-inflammatory agent 5% bufexamac as well as to 0.75% fluocortin butyl ester, a further glucocorticoid. With regard to neurodermitis, Kamillosan cream not only shows the same therapeutic effect as 0.25% hydrocortisone but is even of marked superiority towards other reference products.

Topics: Adolescent; Adult; Aged; Bufexamac; Chamomile; Clinical Trials as Topic; Dermatitis; Dermatitis, Contact; Dermatitis, Seborrheic; Diflucortolone; Female; Fluocortolone; Humans; Hydrocortisone; Hydroxamic Acids; Male; Middle Aged; Neurodermatitis; Oils, Volatile; Ointments; Plant Extracts; Plants, Medicinal

10 subjects were assessed using the vasoconstrictor assay technique in a double-blind study in order to evaluate the relative potencies of several diluted and undiluted proprietary corticosteroid preparations. Dermovate ointment achieved a significantly higher score than any other preparation but there was no significant difference between the scores for Betnovate ointment (betamethasone valerate 0.1%), Propaderm Forte cream (beclomethasone dipropionate 0.5%), Propaderm ointment (beclomethasone dipropionate 0.025%), Nerisone Forte ointment (diflucortolone valerate 0.3%), and Nerisone ointment (diflucortolone valerate 0.1%). Furthermore, no significant difference in scores could be demonstrated between Adcortyl ointment (triamcinolone acetonide 0.1%), Ledercort ointment (triamcinolone acetonide 0.1%) and extemporaneous dilutions of these ointments 1 part in 4 in their recommended diluents (triamcinolone acetonide 0.025%). The relevance of these findings to clinical practice is discussed.

Topics: Administration, Topical; Adult; Clobetasol; Diflucortolone; Dose-Response Relationship, Drug; Female; Glucocorticoids; Humans; Male; Triamcinolone Acetonide; Vasoconstriction

In this multicentre, between-patient trial the efficacy and tolerability of a cream, containing 0.05% halometasone and 1% triclosan, was compared with those of Nerisona C cream, containing 0.1% diflucortolone valerate and 1% chlorquinaldol, in 183 patients with acute dermatomycoses. Halometasone/triclosan cream and the comparative cream showed closely similar results with respect to good to very good therapeutic effects (60% versus 57%). However, halometasone/triclosan cream proved superior to the comparative preparation with regard to very good (cured) results (53% versus 46%), an early cure in less than 30 days (41% versus 34%) and onset of action within 3 days of starting the treatment (32% versus 18%). Mycological findings were positive on direct microscopy in 36% and 43% and in culture in 19% and 17% of the patients following treatment with halometasone/triclosan cream and the comparative cream preparation, respectively. Adverse effects were reported in seven out of 108 patients treated with halometasone/triclosan cream and in five out of 107 patients treated with the comparative preparation.

Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Chlorquinaldol; Clinical Trials as Topic; Dermatomycoses; Diflucortolone; Drug Combinations; Female; Fluocortolone; Humans; Hydroxyquinolines; Male; Middle Aged; Phenyl Ethers; Triclosan

90 patients suffering from chronic skin diseases-mainly psoriasis vulgaris-were treated in a double-blind-study for two weeks with topical Clobetasol-17-propionate compared with other topical corticoids. In 81% was seen a better therapeutical effect on the Clobetasol-17-propionate treated skin area.

Topics: Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Betamethasone; Child; Clinical Trials as Topic; Clobetasol; Desoximetasone; Diflucortolone; Double-Blind Method; Eczema; Humans; Middle Aged; Neurodermatitis; Psoriasis

The blanching activities and hence bioavailabilities of the cream, ointment and fatty ointment preparations of Nerisone and Temetex (diflucortolone valerate 0.1%) were evaluated using an occluded and unoccluded blanching assay. These products were compared to Synalar ointment and cream (fluocinolone acetonide 0.025%), established topical corticosteroid preparations. Statistical analysis showed no significant differences between similar formulations of diflucortolone valerate. Significant differences were noted between diflucortolone valerate and fluocinolone acetonide preparations.

Topics: Administration, Topical; Biological Availability; Clinical Trials as Topic; Diflucortolone; Fluocinolone Acetonide; Fluocortolone; Humans; Ointments; Pharmaceutical Vehicles; Pregnadienediols; Skin; Therapeutic Equivalency

Evaluation of cutaneous vasoconstriction after applications of varying duration of topical corticoids on the flexor surfaces of the forearms of 20 patients with intact skin shows a significantly faster blanching effect with diflucortolone valerate ointment than with fluocinolone acetonide and betamethasone valerate ointments. Furthermore, the test shows that even for a highly active preparation, such as the diflucortolone valerate ointment, an application time of less than 3 h only exceptionally leads to vasoconstriction in the healthy skin.

Topics: Administration, Topical; Adrenal Cortex Hormones; Betamethasone; Betamethasone Valerate; Diflucortolone; Fluocinolone Acetonide; Fluocortolone; Humans; Occlusive Dressings; Ointments; Pregnadienediols; Skin; Time Factors; Vasomotor System

Topical treatment of skin disease needs to be strategic to ensure high drug concentration in the skin with minimum systemic absorption.. The aim of this study was to produce semisolid nanostructured lipid carrier (NLC) formulations, for topical delivery of the corticosteroid drug, diflucortolone valerate (DFV), with minimum systemic absorption.. NLC formulations were developed using a high shear homogenization combined with sonication, using Precirol® ATO5 or Tristearin® as the solid lipid, Capryol™ or isopropyl myristate as the liquid lipid and Poloxamer® 407 as surfactant. The present study addresses the influence of different formulations composition as solid lipid, liquid lipid types and concentrations on the physicochemical properties and drug release profile from NLCs.. DFV-loaded NLC formulations possessed average particle size ranging from 160.40 nm to 743.7 nm with narrow polydispersity index. The encapsulation efficiency was improved by adding the lipid-based surfactants (Labrasol® and Labrafil® M1944CS) to reach 68%. The drug release from the investigated NLC formulations showed a prolonged release up to 12 h. The dermatopharmacokinetic study revealed an improvement in drug deposition in the skin with the optimized DFV-loaded NLC formulation, in contrast to a commercial formulation.. NLC provides a promising nanocarrier system that work as reservoir for targeting topical delivery of DFV.

Topics: Diflucortolone; Drug Carriers; Drug Compounding; Drug Delivery Systems; Humans; Lipids; Nanostructures; Particle Size; Skin; Surface Properties; Tissue Distribution

Atopic dermatitis (AD) is a chronic and relapsing skin disease with severe eczematous lesions. Long-term topical corticosteroid treatment can induce skin atrophy, hypopigmentation and transepidermal water loss (TEWL) increase. A new treatment approach was needed to reduce the risk by dermal targeting. For this purpose, Betamethasone valerate (BMV)/Diflucortolone valerate (DFV)-loaded liposomes (220-350 nm) were prepared and incorporated into chitosan gel to obtain adequate viscosity (∼13 000 cps). Drugs were localized in stratum corneum + epidermis of rat skin in ex-vivo permeation studies. The toxicity was assessed on human fibroblast cells. In point of in-vivo studies, pharmacodynamic responses, treatment efficacy and skin irritation were evaluated and compared with previously prepared nanoparticles. Liposome/nanoparticle in gel formulations produced higher paw edema inhibition in rats with respect to the commercial cream. Similar skin blanching effect with commercial creams was obtained via liposome in gels although they contain 10 times less drug. Dermatological scoring results, prognostic histological parameters and suppression of mast cell numbers showed higher treatment efficiency of liposome/nanoparticle in gel formulations in AD-induced rats. TEWL and erythema measurements confirmed these results. Overview of obtained results showed that liposomes might be an effective and safe carrier for corticosteroids in skin disease treatment.

Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Animals; Betamethasone Valerate; Chemistry, Pharmaceutical; Diflucortolone; Drug Carriers; Drug Delivery Systems; Economics, Pharmaceutical; Epidermis; Humans; Liposomes; Nanoparticles; Particle Size; Rats; Skin Absorption

Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Candidiasis, Vulvovaginal; Clobetasol; Diflucortolone; Female; Herpes Genitalis; Humans; Middle Aged; Papillomavirus Infections; Telangiectasis; Time Factors; Vulvar Lichen Sclerosus; Young Adult

Topics: Anti-Inflammatory Agents; Diflucortolone; Drug Eruptions; Eczema; Female; Foot; Humans; Hypopigmentation; Leg; Middle Aged

Undetected tinea pedis in a patient with diabetes can lead to serious bacterial infections with potentially serious consequences, such as foot amputations. Here we report on a 60-year-old patient with diabetes presenting with pain, severe pruritus, and malodour in the foot's interdigital area, and subsequently, diagnosed with inflammatory tinea pedis with bacterial superinfection. The patient was successfully treated with Travocort cream containing isoconazole nitrate 1% and diflucortolone valerate 0.1%; marked improvement occurred within 5 days.

Topics: Administration, Topical; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Diabetes Complications; Diflucortolone; Humans; Male; Miconazole; Middle Aged; Skin Diseases, Bacterial; Superinfection; Tinea Pedis; Treatment Outcome

There have been few published reports on the human transmission of Trichophyton mentagrophytes, a zoophilic fungus frequently occurring in pets. Here we report on 2 girls, living with a pet dwarf rabbit, who presented with inflammatory skin lesions positive for T. mentagrophytes and subsequently diagnosed as zoophile tinea faciei and tinea corporis. The patients were successfully treated with systemic terbinafine and 2-week therapy with Travocort cream containing isoconazole nitrate 1% and diflucortolone valerate 0.1%.

Topics: Administration, Oral; Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Child; Diflucortolone; Environmental Exposure; Female; Humans; Miconazole; Naphthalenes; Pets; Rabbits; Terbinafine; Tinea; Treatment Outcome; Trichophyton

Trichophyton mentagrophytes is the dermatophyte species most commonly reported in cases of guinea pig-associated dermatophytosis (or guinea pig fungus) a condition that more often affects children than adults. In this case, a 13-year-old girl with recent direct contact with guinea pigs presented with a previously undertreated inflammatory skin lesion on the left side of her upper body, which was positive both for Trichophyton mentagrophytes and Staphylococcus epidermidis. The condition was subsequently diagnosed as tinea corporis due to Trichophyton mentagrophytes with concomitant bacterial infection and effectively treated with 2 weeks of twice-daily application of Travocort cream containing isoconazole nitrate 1% and diflucortolone valerate 0.1%. Visible improvement in the lesion was apparent after only 1 week of treatment.

Topics: Administration, Topical; Adolescent; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Environmental Exposure; Female; Gram-Positive Bacterial Infections; Guinea Pigs; Humans; Miconazole; Skin Diseases, Bacterial; Staphylococcus epidermidis; Tinea; Treatment Outcome; Trichophyton

Trichophytia infection, paraphrased cuddly toy mycosis, occurs primarily in prepubertal children, occasionally in infants and adults. The presented case shows the highly contagious infection of four family members with Trichophyton mentagrophytes. Effective treatment requires detailed diagnostic: identifying the dermatophyte, finding the infection source, treating the infection carriers. Tinea must be treated systemically and topically because of infectivity and ignitability. Systemic terbinafine or fluconazole treatment and topical fixed combination isoconazole nitrate/diflucortolone valerate are recommended.

Topics: Administration, Oral; Administration, Topical; Adult; Animals; Anti-Inflammatory Agents; Antifungal Agents; Child; Child, Preschool; Diflucortolone; Environmental Exposure; Family Health; Female; Fluconazole; Humans; Male; Miconazole; Naphthalenes; Pets; Terbinafine; Tinea; Treatment Outcome; Trichophyton

The objective of this study was to prepare a suitable formulation for dermal delivery of diflucortolone valerate (DFV) that would maintain the localization in skin layers without any penetration and to optimize efficiency of DFV. Drug-loaded lecithin/chitosan nanoparticles with high entrapment efficiency (86.8%), were successfully prepared by ionic interaction technique. Sustained release of DFV was achieved without any initial burst release. Nanoparticles were also incorporated into chitosan gel at different ratios for preparing a more suitable formulation for topical drug delivery with adequate viscosity. In ex-vivo permeation studies, nanoparticles increased the accumulation of DFV especially in the stratum corneum + epidermis of rat skin without any significant permeation. Retention of DFV from nanoparticle in chitosan gel formulation (0.01%) was twofold higher than commercial cream, although it contained ten times less DFV. Nanoparticles in gel formulations produced significantly higher edema inhibition in rats compared with commercial cream in in-vivo studies. Skin blanching assay using a chromameter showed vasoconstriction similar to that of the commercial product. There were no barrier function changes upon application of nanoparticles. In-vitro and in-vivo results demonstrated that lecithin/chitosan nanoparticles in chitosan gel may be a promising carrier for dermal delivery of DFV in various skin disorders.

Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Chitosan; Diflucortolone; Drug Carriers; Edema; Gels; Lecithins; Male; Mechanical Phenomena; Nanoparticles; Particle Size; Rats; Rats, Wistar; Skin; Skin Absorption; Vasoconstriction

Topics: Aged, 80 and over; Anti-Inflammatory Agents; Clobetasol; Diflucortolone; Erythema; Humans; Male; Prednisone; Sweet Syndrome

Many tinea inguinalis infections are characterized by pronounced inflammatory lesions and pruritus. Therefore, a therapy with a topical corticosteroid in addition to a topical antimycotic agent might be beneficial. In this multicenter, retrospective study, we compared the mycological and clinical efficacy and tolerability of isoconazole nitrate alone vs isoconazole nitrate and diflucortolone valerate in 58 adult patients with tinea inguinalis.. Treatment duration was three weeks. The efficacy of the treatment was based on the assessment of several signs and symptoms, which were collected on a 4-point scale. All patients were examined clinically before the beginning of the treatment, one week later, two weeks later, and at the end of the treatment. Mycological examinations were performed before the beginning of the treatment and at the end of the study.. Treatment results with the combination of isoconazole nitrate and diflucortolone valerate were superior regarding erythema and pruritus. Both erythema and pruritus resolved in a larger percentage of patients and more quickly. Both regimens were well tolerated. Mycological cure rates were similar in both groups of patients.. Combination therapy with isoconazole nitrate and diflucortolone valerate is an effective and well-tolerated regimen in adult patients with tinea inguinalis.

Topics: Administration, Cutaneous; Adolescent; Adult; Antifungal Agents; Diflucortolone; Drug Therapy, Combination; Erythema; Humans; Male; Miconazole; Middle Aged; Pruritus; Retrospective Studies; Time Factors; Tinea; Treatment Outcome; Young Adult

We describe a 73-year-old Japanese man with papuloerythroderma overlapped with monoclonal gammopathy of undetermined significance (MGUS). Clinically, prominent erythroderma was associated with disseminated pruriginous papules, which were characteristically spared on the axillary and inguinal regions, the cubital and popliteal fossae as well as abdominal and small positional folds. Histopathologically, there was a significant perivascular infiltrate of lymphohistiocytic cells intermingled with eosinophils in the upper dermis. A biochemical profile revealed the presence of immunoglobulin G kappa chain type monoclonal protein in the serum but the absence of hematological neoplasms. We diagnosed the patient as papuloerythroderma with MGUS, and treated him with narrow-band ultraviolet B and topical steroid. His skin changes were improved, but the sharp gamma-globulin peak remained in the electrophoresis of serum protein. This case suggests an association between papuloerythroderma and MGUS.

Topics: Aged; Dermatitis, Exfoliative; Diflucortolone; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Male; Paraproteinemias; Ultraviolet Therapy

Incontinentia pigmenti (IP) is a rare genodermatosis caused by a mutation of nuclear factor kappa B essential modulator gene. There is no specific treatment for IP, therefore it has been claimed that there is no effective treatment to hasten resolution of any of the phases of IP. However, the initial vesiculobullous stage of IP is characterized histopathologically by eosinophilic inflammation, which is expected to respond to corticosteroids. An 18-day-old female neonate was seen, with vesicles on her trunk and limbs diagnosed as the vesiculobullous stage of IP. The patient was treated with a double-compound cream containing a potent corticosteroid (difluocortolone valerate 0.1%) and an antiseptic (chlorquinaldol 1%), to be applied to the lesions twice daily. Five days later, resolution of the lesions was almost complete. As chlorquinaldol has no known anti-inflammatory activity, we attribute this improvement to difluocortolone valerate. This case shows that early lesions of IP with eosinophilic inflammation are treatable.

Topics: Administration, Cutaneous; Chlorquinaldol; Diflucortolone; Female; Glucocorticoids; Humans; Incontinentia Pigmenti; Infant, Newborn

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Dermatomycoses; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Global Health; Humans; Internationality; Miconazole; Tinea; Treatment Outcome

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Groin; Humans; Male; Miconazole; Skin; Tinea; Treatment Outcome

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Groin; Humans; Male; Miconazole; Middle Aged; Ointments; Skin; Tinea; Treatment Outcome; Trichophyton

Topics: Aged; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Groin; Humans; Male; Miconazole; Ointments; Skin; Tinea; Treatment Outcome

Topics: Administration, Cutaneous; Aged; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Humans; Leg; Male; Miconazole; Ointments; Skin; Thorax; Tinea; Treatment Outcome; Trichophyton

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Back; Child; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Female; Humans; Miconazole; Ointments; Skin; Tinea; Treatment Outcome; Trichophyton

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Foot Dermatoses; Humans; Leg; Male; Miconazole; Ointments; Onychomycosis; Skin; Tinea; Treatment Outcome; Trichophyton

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Breast; Candida; Candidiasis, Cutaneous; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imidazoles; Intertrigo; Miconazole; Ointments; Skin; Treatment Outcome

Topics: Aged; Anti-Inflammatory Agents; Antifungal Agents; Axilla; Candida; Candidiasis, Cutaneous; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Humans; Intertrigo; Male; Miconazole; Ointments; Skin; Treatment Outcome

Topics: Adult; Anti-Inflammatory Agents; Antifungal Agents; Balanitis; Candida albicans; Candidiasis, Cutaneous; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Eczema; Genitalia, Male; Humans; Intertrigo; Male; Miconazole; Ointments; Treatment Outcome

Topics: Adult; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Combinations; Drug Therapy, Combination; Humans; Male; Miconazole; Ointments; Skin; Tinea Pedis; Toes; Treatment Outcome

Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Diflucortolone; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Foot; Humans; Male; Miconazole; Ointments; Skin; Tinea Pedis; Treatment Outcome

Topics: Administration, Topical; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Clobetasol; Cushing Syndrome; Diaper Rash; Diflucortolone; Drug Overdose; Glucocorticoids; Humans; Hydrocortisone; Infant

Prolonged application of topical steroids transiently suppresses the hypothalamic-pituitary-adrenal axis (HPA). Infants who are exposed to topical corticosteroids have greater risk for Cushing's syndrome or adrenocortical insufficiency caused by suppression of the HPA axis because glucocorticoids are highly absorbed through the diaper area. Here, we report six infants (four girls, two boys) aged between 3 and 8 months who were exposed to potent topical corticosteroids (clobetasol propionate and diflucortolone valerate) by the mother's application without prescription.. We examined the HPA axis and other side effects of the potent glucocorticoid therapy in these infants. After stopping the topical corticosteroid, serum AST, ALT, lipids, morning cortisol and ACTH levels were measured. A low dose ACTH stimulation test was carried out. Hydrocortisone was started for the prevention of glucocorticoid withdrawal syndrome and the dose was gradually decreased. Abdominal ultrasonography was performed to investigate hepatosteatosis.. The ACTH stimulation test showed suppression of the HPA axis in these infants. Hepatomegaly was found in all infants and three of them had hepatosteatosis. Liver transaminase levels were elevated in five infants. Five patients have been followed for 6-14 months. One infant died due to generalized Cytomegalovirus infection.. We emphasize that physicians should be alert for the dangerous side-effects of topical steroids and they should avoid long-term use. Furthermore, parents should be informed about the side-effects when topical steroid treatment is chosen.

Topics: Administration, Topical; Adrenal Insufficiency; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Clinical Chemistry Tests; Clobetasol; Contraindications; Cushing Syndrome; Diaper Rash; Diflucortolone; Drug Overdose; Fatal Outcome; Female; Glucocorticoids; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Infant; Male; Pituitary-Adrenal System

We describe an 81-year-old Japanese patient with erythroderma overlapping with widespread and symmetrical deposits of mucin in the upper dermis. Clinically, the mucinous lesions on the nape and upper trunk were localized papular mucinosis. Histologically, there was a perivascular infiltrate of lymphohistiocytic cells mingled with plasma cells in the upper dermis but no sclerosis. Immunohistochemical staining revealed that more than 90% of these infiltrating plasma cells produced immunoglobulin lambda-chain. Both the erythroderma and generalized mucinosis responded to topical steroid and PUVA therapy. To the best of our knowledge, this is the first case of erythroderma accompanied by generalized mucinosis.

Topics: Administration, Cutaneous; Aged, 80 and over; Anti-Inflammatory Agents; Biopsy; Dermatitis, Exfoliative; Diflucortolone; Humans; Male; Mucinoses; PUVA Therapy; Skin; Treatment Outcome

Effects of a topical corticosteroid drug, diflucortolone valerate, on the mRNA expressions for four CC- and four CXC-chemokines, which have been reported to be associated with recruitment of different kinds of proinflammatory and inflammatory cells, were investigated by RT-PCR in mice with 2,4,6-trinitrochlorobenzene (TNCB)-induced contact hypersensitivity (CHS) response. All of the eight gene expressions were clearly up-regulated in the lesion site of the CHS response up to 24 h post-challenge of TNCB at which ear swelling response reached a peak, so that heavy infiltration of inflammatory cells consisting mainly of mononuclear cells and neutrophils was likely induced by these chemokines. Topical treatment with diflucortolone valerate suppressed completely the infiltrates as well as the ear swelling response. In addition, the up-regulation of gene expressions for these eight chemokines were suppressed by the treatment, indicating that the corticosteroid drug attenuates the expression of chemokine genes essential for orientating nonspecific skin response to hapten-specific CHS response through the recruitment of inflammatory cells from the circulation into the tissue site.

Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Chemokines; Dermatitis, Contact; Diflucortolone; Ear; Gene Expression; Male; Mice; Mice, Inbred BALB C; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors

Topics: Administration, Topical; Adult; Choroid Diseases; Dermatitis, Seborrheic; Diflucortolone; Fluorescein Angiography; Glucocorticoids; Humans; Hydrocortisone; Male; Retinal Diseases; Tinea Versicolor; Visual Acuity

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone Valerate; Dermatitis; Diflucortolone; Eczema; Eyelid Diseases; Female; Glaucoma; Glucocorticoids; Humans; Intraocular Pressure; Male; Ointments; Scotoma; Visual Fields

The local anti-inflammatory activity and systemic side effects of NM-135 (6alpha,9-difluoro-11beta-hydroxy-16alpha-methyl-21[[2 ,3,4,6-tetrakis-O-(4-methylbenzoyl)-beta-D-glucopyranosyl]oxy]-pregna-1, 4-diene-3,20-dione) in croton oil-induced granuloma pouches and ear edema in rats were studied. The local anti-inflammatory activity of NM-135 was stronger than that of betamethasone 17-valerate (BV). As to systemic side effects, BV and diflucortolon valerate (DFV) caused thymolysis at the doses required for the anti-inflammatory activity. In contrast, no clear systemic side effect was observed in rats administered NM-135 at the dose producing the anti-inflammatory activity. These results suggest that NM-135 is a drug exhibiting a high degree of dissociation between the local anti-inflammatory activity and systemic side effects.

Topics: Animals; Anti-Inflammatory Agents; Atrophy; Betamethasone Valerate; Croton Oil; Diflucortolone; Disease Models, Animal; Dose-Response Relationship, Drug; Ear; Edema; Exudates and Transudates; Glucocorticoids; Granuloma; Inflammation; Male; Organ Size; Pregnanediones; Prodrugs; Rats; Rats, Sprague-Dawley; Thymus Gland

Epidermal cells express two retinotic acid-binding proteins (CRABP I and II). Because CRABP II protein is strongly induced by topical retinoic acid, the respective roles of the two proteins in the pharmacological activity and toxicity of topical retinoids deserve particular attention. Since topical steroids diminish the irritation induced by retinoic acid (RA), whereas retinoic acid may counteract the atrophogenic effects of steroids, the possible interplay of both compounds in the expression of CRABP I and II appeared worth studying. We have analyzed the effects of topical application of triamcinolone acetonide (TA) on the retinoic acid-induced altered expression of CRABP I and II in normal human skin, at the protein and mRNA levels. We found that CRABP II protein and mRNA were strongly increased upon retinoic acid application: this induction was significantly inhibited by concomitant application of triamcinolone acetonide; a more potent steroid, difluocortolone valerate, was also found to diminish normal endogenous expression of CRABP II. In contrast, CRABP I protein was decreased by topical retinoic acid, and the down modulating effect of retinoic acid was counteracted by triamcinolone acetonide.

Topics: Administration, Topical; Adult; Diflucortolone; Female; Humans; Male; Middle Aged; Receptors, Retinoic Acid; RNA, Messenger; Skin; Triamcinolone Acetonide

Diflucortolone-21-valerate was tested for the preparation of "Diflucortolone-21-valerate Reference Standard (Control 871)". Analytical data obtained were as follows: loss on drying, 0.05%; infrared spectrum, 1745, 1727, 1667, 1625, 1611, 1169 cm-1; ultraviolet spectrum, lambda max = 239 nm; absorbance, E1%1cm (239 nm) = 348.8; optical rotation, [alpha]20D: + 100.8 degrees; melting point, 203.2 degrees C; thin-layer chromatography, three contaminants were detected; high-performance liquid chromatography, two contaminants were detected; fluorine, 8.06%. On the basis of those results, this material was authorized as the National Institute of Hygienic Sciences Reference Standard (Control 871).

Topics: Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Diflucortolone; Drug Contamination; Fluocortolone; Japan; Pharmacopoeias as Topic; Reference Standards; Spectrophotometry, Infrared

A hemorrhoid model was prepared by means of application of croton oil onto the recto-anus of rats. Cotton swab soaked with the inducer, which consisted of water, pyridine, diethylether and 6% croton oil in diethylether, was inserted into the anus. The following conditions were found to be optimal for preparing the model: cotton swab containing 0.16 ml of the inducer solution was applied to the anus of a 6 week-old rat (body wt. about 140 g) for 10 sec. The edema developed linearly until 7-8 hr after application, and the severity of the edema was sustained almost constantly for more than 24 hr. Macroscopic observations at 6 hr p. a. revealed homogeneous and consistent inflammation in the recto-anus applied region. Histological observation showed appearance of edema, infiltration of fibrin, inflammatory cells, vasodilation, blood congestion and medium to high degrees of necrosis in the mucosal epithelium. Thus this model was useful for evaluating the effect of anti-hemorrhoidal drugs on intumescence and vasodilatation. The efficacy of diflucortolone valerate, hydrocortisone caproate and hydrocortisone was evaluated in this model. Wet weight and vasopermeability increased by the inducer was suppressed strongly by simultaneous application of the corticoids, and the degree of suppression was parallel with the potency of the glucocorticoid activity. Compared to Scheriproct, Posterisan forte, Posterisan and Borraginol N, Neriproct showed the strongest effects in the protection against and treatment of the experimental hemorrhoid. Scheriproct, which was less active than Neriproct, was also found to have higher efficacy than the others.

Topics: Animals; Anti-Inflammatory Agents; Croton Oil; Diflucortolone; Disease Models, Animal; Drug Combinations; Fluocortolone; Hemorrhoids; Hydrocortisone; Lidocaine; Male; Rats; Rats, Inbred Strains; Rectum

Several glucocorticoids as a cream formulation were applied to the recto-anus of the croton-oil-induced hemorrhoid rat. Among the steroids tested, i.e. diflucortolone valerate (DFV), prednisolone (PS), hydrocortisone caproate (HC), and hydrocortisone (H), DFV was found to suppress inflammation most effectively. The effect of DFV was not affected by combination with lidocaine. In this model, the analgesic effect of lidocaine was apparently prolonged by an increase of the threshold for pain by the anti-inflammatory effect of DFV. This additive effect is regarded as a merit of the combination in Neriproct. Therapeutic effects of Neriproct and several anti-hemorrhoid drugs were also examined by using a hemorrhoid model with abrasive irritation compared to those obtained by the croton-oil model. In both models, efficacy of Neriproct was superior to that of the other drugs such as Scheriproct, Proctosedyl, Posterisan forte, Borraginol N, Posterisan and Borraza G. Microscopic observation showed that destruction of the mucus epithelium, necrosis of the mucus layer, infiltration of inflammatory cells and vasodilatation in the croton-oil model were also suppressed markedly by Neriproct application. No difference was observed in the efficacy between the cream and suppository formulation of Neriproct. Suppression of wound healing was found with a dosage of DFV lower than those of PS, HC and H. However, the efficacy ratio of the wound-healing suppression and anti-inflammation of DFV was the largest among the steroids tested.

Topics: Animals; Anti-Inflammatory Agents; Croton Oil; Diflucortolone; Disease Models, Animal; Dosage Forms; Drug Combinations; Fluocortolone; Hemorrhoids; Lidocaine; Male; Rats; Rats, Inbred Strains; Rectum

More than 10 years ago, diflucortolone valerate (Nerisone, Nerisona) was introduced in Germany and soon after in Asian countries in a concentration of 0.1% in cream, ointment and fatty ointment bases. 897 patients were included in the first Southeast Asian multicentre trial with these 3 formulations, and good efficacy and tolerability combined with a rapid onset of effect were shown. These results were confirmed later in Indonesia in an extended follow-up trial which included 1295 patients. A combination of 0.1% diflucortolone valerate with 1.0% chlorquinaldol was introduced after a multicentre Southeast Asian trial involving 8668 patients with inflammatory or allergic skin conditions for which a supplementary anti-infective treatment, for prophylaxis or therapy, was considered to be indicated. Excellent results were obtained in terms of efficacy, tolerability and cosmetic properties. A randomised double-blind trial comparing this preparation with a so-called 'shotgun' combination containing 0.05% betamethasone 17-valerate, 0.1% gentamicin, 1.0% tolnaftate and 1.0% clioquinol in 288 patients in the Philippines resulted in a better efficacy for the diflucortolone preparation in the 80 patients with bacterially or mycotically infected skin diseases. A 0.3% concentration of diflucortolone valerate was developed and introduced as a high potency topical corticosteroid. A trial in the Philippines which involved 143 patients with mostly severe chronic recurrent and resistant corticosteroid-responsive skin disease confirmed a pronounced clinical efficacy with a low incidence of side effects. For the treatment of inflammatory or eczematised dermatomycosis. 0.1% diflucortolone was combined with 1.0% isoconazole nitrate (Travocort). In a randomised double-blind study of 294 patients in Thailand, this preparation was compared with a plain 1.0% clotrimazole formulation. The results were significantly better for the diflucortolone plus isoconazole nitrate combination in terms of remission of symptoms, and after 1 week the mycological cure rates were also better, as shown in potassium hydroxide and culture investigations. It is concluded, therefore, that diflucortolone valerate in the available galenic bases and in effective combinations with other agents has been proven in extensive clinical trials to be a valuable therapeutic tool in dermatological practice.

Topics: Asia; Chlorquinaldol; Dermatomycoses; Diflucortolone; Fluocortolone; Humans; Miconazole; Ointments; Skin Diseases

Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chlorquinaldol; Dermatitis, Contact; Diflucortolone; Drug Evaluation; Drug Therapy, Combination; Female; Fluocortolone; Humans; Hydroxyquinolines; Male; Middle Aged

Comparative systemic and topical toxicity in male rats treated on the dorsal skin for 14 consecutive days with a volume of 0.15 g/100 g (body weight) of 0.1% hydrocortisone 17-butyrate 21-propionate (HBP) ointment, 0.05% clobetasol propionate (CP) ointment, 0.1% predonisolone 17-valerate 21-acetate (PVA) ointment and 0.1% diflucortolone valerate (DV) ointment was studied. In all the treated groups body weight gain was suppressed, serum concentration of total cholesterol and triglycerides increased and the lymphatic tissues and skin were atrophic. The DV and CP groups had adrenal atrophy and renal lesions, and the DV group also had gastric and hepatic lesions. The systemic effect of HBP ointment was weaker than that of the other drugs (DV greater than CP much greater than PVA greater than HBP). All the drugs significantly reduced the skin fold thickness in treated areas throughout the application period. The dermal atrophic effect of HBP ointment was also relatively weaker than that of the other drugs. From the above evidence, it was concluded that HBP ointment was less toxic than the other topical corticosteroids.

Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Clobetasol; Diflucortolone; Hydrocortisone; Male; Ointments; Prednisolone; Rats; Rats, Inbred Strains; Skin

In order to quantify the intensity of skin blanching and thus predict the bioavailability of topical corticoids, a physical device allowing the measurement of light reflected from skin without any contact between the probe and the skin was used (Leveque et al., 1984). Three series of experiments were carried out: firstly, to assess the vasoconstrictor potency of four corticoids; secondly, to show the influence of the vehicle on the bioavailability of the same drug under various galenic forms, such as fatty ointments or water in oil (W/O) and oil in water (O/W) creams; thirdly, to determine the reservoir effects, if any, of some of these formulations. The results confirm previous findings about the potency of hydrocortisone acetate, triamcinolone 17-acetonide, betamethasone 17-valerate, diflucortolone valerate and clobetasol 17-propionate.

Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone Valerate; Biological Availability; Clobetasol; Color; Diflucortolone; Humans; Hydrocortisone; Ointments; Pharmaceutical Vehicles; Photometry; Skin; Triamcinolone Acetonide; Vasoconstriction

Topics: Administration, Oral; Administration, Topical; Adrenal Cortex; Adult; Anti-Inflammatory Agents; Betamethasone; Budesonide; Clobetasol; Diflucortolone; Dose-Response Relationship, Drug; Eczema; Female; Humans; Hydrocortisone; Male; Middle Aged; Ointments; Pregnenediones; Psoriasis

The concentration of diflucortolone-21-valerate (DFV) in the different layers of human skin was investigated after topical application of Nerisona (0.1%) as a function of the formulation (fatty ointment, ointment and creme), of the duration of exposition and of the condition of the skin. From all galenic formulations DFV penetrated rapidly into the horny layer. Mean highest concentrations were determined 4 h after application with approx. 300 micrograms/ml (ca. 600 mumol/l) after treatment with fatty ointment and ointment and with approx. 500 micrograms/ml (ca. 1000 mumol/l) after treatment with the cream. The corticoid concentration decreased in the horny layer from distal to proximal by 1.5 to 2 decades. After application to damaged skin - as a model for diseased skin - the local corticoid concentrations in all skin layers were distinctly higher than after application to intact skin at all time points investigated. DFV penetrates selectively into the damaged skin. The systemic load caused by percutaneous absorption through intact skin is neglectable.

Topics: Adult; Diflucortolone; Fluocortolone; Humans; Ointments; Skin Absorption; Time Factors

Diflucortolone valerianate, a new fluorinated corticosteroid for tropical use, was applied in 52 patients suffering of diverse inflammatory dermatosis. The maximum observation time was 3 weeks. The results were, very good in 63.46%; good in 28.84%; regular in 1.92 %, and bad in 5.76%. In 73.7% of the cases good results were obtained in less than 2 weeks. The cream was cosmetically well accepted and there were no observed side effects.

Topics: Adolescent; Adult; Child; Child, Preschool; Dermatitis; Diflucortolone; Drug Evaluation; Fluocortolone; Humans; Infant; Middle Aged; Ointments

In 20 healthy volunteers of both sexes the vasoconstrictive activity of diflucortolone valerate in two of its commercially available formulations (water-in-oil emulsion and pure fat base) was compared with that of four other substances: fluocinonide; betamethasone-17,21-dipropionate; hydrocortisone-17-butyrate; and clobetasol-17-propionate in corresponding galenical formulations. The visual assessment of vasoconstrictive activity after 10 hours revealed a statistically significant superiority of diflucortolone valerate in its fat base over the corresponding galenical formulations of fluocinonide, clobetasol-17-propionate, and hydrocortisone-17-butyrate. Diflucortolone valerate in a water-in-oil emulsion was statistically better after eight hours than the cream formulations of fluocinonide; clobetasol-17-propionate, and betamethasone-17,21-dipropionate.

Topics: Administration, Topical; Anti-Inflammatory Agents; Diflucortolone; Female; Fluocortolone; Glucocorticoids; Humans; Male; Regional Blood Flow; Skin; Skin Tests; Vasoconstriction

Topics: Dermatitis; Diflucortolone; Drug Evaluation; Eczema; Fluocortolone; Humans; Neurodermatitis; Pregnadienediols; Psoriasis